By: Benzinga
February 07, 2013 at 10:38 AM EST
UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence
Credit Suisse initiated AbbVie (NYSE: ABBV ) with a Neutral rating and a $37.00 price target. Credit Suisse noted, "AbbVie's cross-currents imply minimal stock movement from current price. Growth is modest with 2013-2020 sales and EPS CAGR at 2% and 3% respectively and only 20% revenue contribution from the
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here